

## Attention: Medicaid Fee-for-Service Providers Dispense Brand Drugs When Less Expensive Program

Effective August 30, 2012,

**Uroxatral** will be **removed** from the Dispense Brand Drugs When Less Expensive Program  
and

**Symbyax, Ziagen tablet and Catapres-TTS** will be **added** to the Dispense Brand Drugs When Less Expensive Program

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- **Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription;**
- have a generic copayment;
- will be paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (neither the SMAC nor FUL will be applied)

### IMPORTANT BILLING INFORMATION

Prescription claims submitted to the Medicaid program **do not require** the submission of Dispense As Written/Product Selection Code of '1'; and **Pharmacies can submit any valid NCPDP field (408-D8) value.**

*Current list of Brand name drugs included in this program\* (Date Revised 8/30/2012):*

<b>Adderall XR</b>	<b>Epivir</b>
<b>Arixtra</b>	<b>Kadian</b>
<b>Astelin</b>	<b>Lexapro</b>
<b>Carbatrol</b>	<b>Lovenox</b>
<b>Catapres-TTS</b>	<b>Nasacort AQ</b>
<b>Combivir</b>	<b>Symbyax</b>
<b>Concerta</b>	<b>Valtrex</b>
<b>Diastat</b>	<b>Ziagen tablet</b>
<b>Geodon</b>	

\* List is subject to change

Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs; again promoting the use of the most cost-effective product.